asset sale
Laboratoires Théa Acquires Two Ophthalmic RNA Drugs From ProQR Therapeutics
The divestiture will allow ProQR to develop other pipeline products, including treatments for cholestatic diseases and its RNA-editing technology.
Mustang Bio Reprioritizes Pipeline, Sells Manufacturing Facility to Focus on Lead Assets
The company said it is nixing several pipeline programs and selling a manufacturing plant to uBriGene in order to focus on a CD20 CAR T-cell therapy and other nearer term opportunities.
JP Morgan Healthcare, Day 1: Merck KGaA, Mirati, Agios, Tempus, Bristol Myers, Amgen, and More
On the first day, Amgen detailed the rapid advancement of its KRAS inhibitor and Tempus unveiled an AI device to help oncologists deliver precision oncology.